You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
NMDA Receptor Subtype Selective Modualtors as Alzheimer's Disease Therapeutics
SBC: NEUROP, INC. Topic: NIADESCRIPTION (provided by applicant): Alzheimer's disease (AD) is a devastating neurodegenerative disorder. One of the few drugs used to treat AD is memantine, which inhibits N-methyl-d-aspartate receptors (NMDARs), glutamate receptor subtypes found at nearly all vertebrate excitatory synapses. NMDARs are critically involved in many aspects of nervous system function, including learning and me ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of VPL Vaccine for RSV
SBC: SIGMOVIR BIOSYSTEMS, INC. Topic: NIAIDProject Summary Human respiratory syncytial virus (RSV) is recognized as the single most important viral cause of acute respiratory disease in infants and young children worldwide. Elderly populations and immunocompromised individuals are also at significant risk for serious RSV disease. Despite this very substantial disease burden imposed by RSV worldwide, there are no vaccines available. Severa ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Enable Early and Sensitive In Vivo Detection of Liver Metastasis by Protein-based
SBC: INLIGHTA BIOSCIENCES L.L.C. Topic: NCIDESCRIPTION (provided by applicant): The major barriers limiting the application of MRI to detect small liver lesions and metastasis at the early stage and patient selection for targeted therapy based on molecular imaging of disease biomarkers, are due tothe lack of desired MRI contrast agents capable of enhancing the contrast between normal liver tissues and tumors with high relaxivity, tumor tar ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Smartphone Help for DWI Offenders and Their Families: A B-SMART App
SBC: KLEIN BUENDEL, INC. Topic: NIAAADESCRIPTION (provided by applicant): Driving while intoxicated (DWI) remains a substantial and preventable source of morbidity and mortality in the United States. A variety of sanctions and interventions have been attempted to reduce DWI in the U.S., including enhanced DWI enforcement efforts, stricter drunk driving laws, responsible alcohol beverage service training, and alcohol treatment. The Ig ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Developing a Nrf2 activator for the treatment of scleroderma
SBC: CUREVEDA, LLC Topic: NIAMSDESCRIPTION (provided by applicant): Scleroderma is a devastating autoimmune disease with a chronic course, involving the overproduction of collagen leading to fibrosis of the skin and connective tissues. The disease has a range of symptoms including pain,stiffness and swelling of the joints, shortness of breath and gastrointestinal complications. More than 50% of patients with the aggressive form ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Testing Smad7-based biologics for treating chronic wounds
SBC: Taiga Biotechnologies, Inc. Topic: NIAMSDESCRIPTION (provided by applicant): Chronic skin wounds associated with various diseases (e.g., diabetes) and aberrant healing from acute wounding (e.g., hypertrophic scarring) is a major health care burden, which need scientific discovery-based therapeutic interventions. Our previous studies show that Smad7, a TGFb signaling antagonist, accelerates skin wound healing. We have developed a Smad7 f ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Tiptuximab Immunotherapeutic for Cancer
SBC: Medical Guidance Systems LLC Topic: NCI? DESCRIPTION (provided by applicant): Poor prognosis cancers such as lung cancer, glioblastoma, pancreatic cancer and others have 3 year survival rates that range from 1%-15%. Recent advancements in the development of therapeutic antibodies haveshown promise in other cancers such as breast, head and neck, and colon cancer. The limitations in antibody development are the paucity of cancer ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Clinical Translation of Augmented Reality Visualization for Laparoscopic Surgery
SBC: IGI TECHNOLOGIES, INC Topic: NCIDESCRIPTION (provided by applicant): The overall objective of the proposed research is to fully develop and conduct clinical translation of a novel technology that provides minimally invasive surgeons an ability to visualize exposed organ surfaces as wellas structures hidden by them, together with a true appreciation of depth. A long-standing need in minimally invasive laparoscopic surgery has bee ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
A daily client check-in system for outpatient substance abuse treatment
SBC: COG ANALYTICS, LLC Topic: NIDAAbstract Alcohol and illicit drug use remain highly prevalent in the US, and epidemiological surveillance surveys estimate that over 20.6 million individuals (~ 8% of the US population) meet standard diagnostic thresholds for substance use disorders (SAMHSA, 2011). Outpatient substance abuse treatment is the predominate method of treatment in the US for SUDs, typically involving intermittent cont ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Drug Delivery Method for Sudden Sensorineural Hearing Loss
SBC: WEINBERG MEDICAL PHYSICS, INC. Topic: NIDCDDESCRIPTION (provided by applicant): The ultimate goal of the proposed project is to evaluate and commercialize a combination of proprietary magnet assemblies and magnetic nanoparticles (initially developed by our University STTR partner), that has been shown in preliminary animal studies to improve delivery of medications to the inner ear. Initial animal studies using the system (which uses magne ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health